Description of the cutaneous manifestations of Covid-19 (COVID-PIEL)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/34470
• EU PAS number:
  EUPAS34469
• Study ID:
  34470
• Official title and acronym:
  Description of the cutaneous manifestations of Covid-19 (COVID-PIEL)
• DARWIN EU® study:
  No
• Study countries:
  Spain
• Study description:
  Observational transversal descriptive study with the main objective to describe the clinical characteristics and symptoms of the cutaneous manifestations associated with COVID-19.The secondary objectives are:o Identify the chronology of the cutaneous manifestations associated with COVID-19.o Evaluate the eventual relationship of skin manifestations with current COVID-19 treatments.o Evaluate the relationship of cutaneous manifestations associated with analytical parameters.
• Study status:
  Planned

Research institution and networks

Institutions

Hospital Universitario de Móstoles

Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency for Medicines and Medical Devices, AEMPS)

Spain

Hospital Plato Barcelona, Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria

Study timelines

Date when funding contract was signed

Planned: 31/03/2020

Study start date

Planned: 06/04/2020

Data analysis start date

Planned: 21/04/2020

Date of interim report, if expected

Planned: 21/04/2020

Date of final study report

Planned: 30/04/2020

Sources of funding

Other

More details on funding

Principal Investigators

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

ACG-CLO2020-01Agencia Española del Medicamento